Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Down 23.9% in March

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 194,500 shares, a drop of 23.9% from the February 28th total of 255,600 shares. Based on an average daily trading volume, of 953,700 shares, the short-interest ratio is currently 0.2 days. Currently, 6.5% of the company’s stock are short sold.

Institutional Trading of Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. Citadel Advisors LLC lifted its stake in Clearmind Medicine Inc. (NASDAQ:CMND) by 115.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,158 shares of the company’s stock after purchasing an additional 20,429 shares during the period. Citadel Advisors LLC owned approximately 0.89% of Clearmind Medicine worth $53,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 96.05% of the company’s stock.

Clearmind Medicine Stock Up 0.5 %

NASDAQ:CMND traded up $0.01 during midday trading on Wednesday, hitting $1.04. 12,417 shares of the company were exchanged, compared to its average volume of 1,044,325. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.01. Clearmind Medicine has a fifty-two week low of $0.95 and a fifty-two week high of $2.30. The company has a market capitalization of $4.41 million, a PE ratio of -0.55 and a beta of 1.02. The company has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.34.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, March 13th. The company reported ($0.24) earnings per share for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.